US 11160810
Fused imidazo-piperidine JAK inhibitor compound
granted A61KA61K31/5377A61K9/0019
Quick answer
US patent 11160810 (Fused imidazo-piperidine JAK inhibitor compound) held by Theravance Biopharma R&D IP, LLC expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K31/5377, A61K9/0019, A61K9/0048, A61K9/10